All In Biotech

Drug Trial Radar · NCT06247735

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

A Phase 2, Randomized, Placebo-controlled, Parallel Group, Multicenter 12-week Study With a 52-week Extension to Evaluate the Efficacy and Safety of Two Doses of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid and/or Obeticholic Acid Treatment

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Feb 7, 2024

Primary completion

Jun 26, 2025

Study completion Jul 23, 2026

Sponsor

Lead sponsor
Kowa Research Institute, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • K-808 (Dose A)Drug

    Administered orally once daily

  • K-808 (Dose B)Drug

    Administered orally once daily

  • PlaceboDrug

    Administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in serum alkaline phosphatase (ALP)Time frame: Baseline to Week 12

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • UA Thomas D. Boyer Liver Institute

    Tucson, Arizona

  • Southern California Research Center - Coronado

    Coronado, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Velocity Clinical Research

    Santa Ana, California

  • Peak Gastroenterology Associates Colorado Springs

    Colorado Springs, Colorado

  • University of Florida Hepatology Research at CTRB

    Gainesville, Florida

  • Florida Research Institute

    Lakewood Rch, Florida

  • University of Miami Leonard M. Miller School of Medicine

    Miami, Florida

  • Springfield Clinic

    Springfield, Illinois

  • Mercy Medical Center - Mcauley Plaza

    Baltimore, Maryland

  • CommonSpirit Health Research Institute

    Omaha, Nebraska

  • New York University Hepatology Associates

    New York, New York

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Einstein Medical Center

    Philadelphia, Pennsylvania

  • Rapid City Medical Center

    Rapid City, South Dakota

  • Vanderbilt Digestive Disease Center

    Nashville, Tennessee

  • Pioneer Research Solutions

    Houston, Texas

  • UVA Health - University of Virginia Health System

    Charlottesville, Virginia

  • Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists

    Norfolk, Virginia

  • Liver Institute Northwest

    Seattle, Washington

  • (G.I,R,I) GI Research Institute

    Vancouver, British Columbia, Canada

  • Office of Dr. Gauthier

    North Bay, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)

    Montreal, Quebec, Canada

  • 306

    Fukui, Japan

  • 313

    Fukuoka, Japan

  • 305

    Hamamatsu, Japan

  • 308

    Hirakata, Japan

  • 309

    Hiroshima, Japan

  • 304

    Isehara, Japan

  • 312

    Kanazawa, Japan

  • 307

    Matsumoto, Japan

  • 311

    Ōmura, Japan

  • 302

    Sapporo, Japan

  • Teine Keijinkai Hospital

    Sapporo, Japan

  • 303

    tabashi City, Japan

  • 314

    Yokohama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.